Integra Lifesciences (NASDAQ:IART) is scheduled to post its quarterly earnings results before the market opens on Wednesday, July 24th. Analysts expect Integra Lifesciences to post earnings of $0.65 per share for the quarter. Integra Lifesciences has set its FY 2019 guidance at $2.65-2.72 EPS and its FY19 guidance at $2.65-2.72 EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.04. Integra Lifesciences had a return on equity of 15.60% and a net margin of 5.60%. The firm had revenue of $359.69 million during the quarter, compared to analyst estimates of $361.12 million. During the same quarter in the previous year, the business earned $0.58 EPS. Integra Lifesciences’s revenue for the quarter was up .7% compared to the same quarter last year. On average, analysts expect Integra Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Shares of Integra Lifesciences stock opened at $54.66 on Tuesday. The company has a current ratio of 2.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.95. Integra Lifesciences has a twelve month low of $42.14 and a twelve month high of $66.41. The company has a 50-day simple moving average of $52.82. The stock has a market cap of $4.65 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.64 and a beta of 1.07.

Several equities analysts recently weighed in on the company. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Oppenheimer boosted their price objective on Chipotle Mexican Grill from $400.00 to $525.00 and gave the stock an “underperform” rating in a research note on Thursday, April 25th. Zacks Investment Research upgraded Hanmi Financial from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th. Finally, ValuEngine lowered Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $58.64.

In other news, Director Christian S. Schade sold 15,658 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $51.56, for a total value of $807,326.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Glenn Coleman sold 3,650 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $55.00, for a total value of $200,750.00. Following the completion of the sale, the chief operating officer now owns 25,160 shares of the company’s stock, valued at $1,383,800. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by insiders.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Reverse Stock Split

Earnings History for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.